2seventy bio

Youtube Subscribe

Open: 5.59 Close: 4.72 Change: -0.87

You'll be sorry if you don't use an AI to decide whether to invest in 2seventy bio Stock.

Are looking for the most relevant information about 2seventy bio? Investor spend a lot of time searching for information to make investment decisions in 2seventy bio. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about 2seventy bio are: bio, report, company, earnings, year, TSVT, late, and the most common words in the summary are: inc, bio, biotech, stock, company, news, therapeutic, . One of the sentences in the summary was: The consensus from seven analysts covering the company is for revenues …

Concept Map

Semantic Network

Stock Summary

Morgan Stanley downgraded 2seveny bio from an “overweight” rating to an ‘equal weight” Morgan Stanley lowered their price objective from $25.00 to $13.00. CEO Nick Leschly.

Today's Summary

Analysts estimate that 2seveny bio will report an earnings per share (EPS) of $-0.99. The consensus from seven analysts covering the company is for revenues of US$74.8m in 2024. Atara Biotherapeutics: After a phase 2 flop late last year, the allogeneic T-cell company has undergone two layoff rounds.

Today's News

2seventy bio TSVT is set to give its latest quarterly earnings report on Tuesday, 2024-03-05. Analysts estimate that 2seveny bio will report an earnings per share (EPS) of $-0.99. The company is bordering on breakeven, according to the 7 American Biotechs. 2seventy bio reported earnings per share of -$1.11.2seventry bio reported fourth quarter and full year 2023 financial results. 2seventy bio, inc. (NASDAQ:TSVT) analysts are cutting their estimates: heres what you need to know. The consensus from seven analysts covering the company is for revenues of US$74.8m in 2024. 2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Hsbc Holdings PLC Invests $339,000 in 2seveny bio. 2seventy Bio stock quotes can also be displayed as NASDAQ : TSVT. If you had invested in 2seveny Bio at $33.62, your return over the last 2 years would have been -85.96%. Atara Biotherapeutics: After a phase 2 flop late last year, the allogeneic T-cell company has undergone two layoff rounds, most recently sending 25% of staff out the door.

Stock Profile

" ExodusPoint Capital Management LPs increased stake in 2seventy bio, inc.: analysts weigh in on stock performance and potential - best stocks. Morgan Stanley downgraded 2seveny bio from an “overweight” rating to an ‘equal weight” Morgan Stanley lowered their price objective from $25.00 to $13.00. 2seventy bio, inc. (NASDAQ:TSVT) shares purchased by zurcher kantonalbank zurich cantonalbank - defense world. (tsvt) - insider trading - insider sales - insider monkey. 2Seventy Bio Inc may pay a varying wage for a given position. 2seventy bio, inc. (nasdaq:tsvt) holdings lifted by credit suisse ag - defense world. Credit Suisse AG owned 2.03% of 2seveny bio worth $10,383,000. CEO Nick Leschly sold 9,060 shares of the company’s stock in a transaction on Thursday, August 3rd. Goldman Sachs Group decreased their price objective on shares of 2 2seventy bio revenue was $91.50 million, an increase of 67.81% compared to the previous years $54.52 million. Analyst Consensus: Strong Buy Stock Forecasts News All Videos Press Press Press Releases."

Keywords

The game is changing. There is a new strategy to evaluate 2seventy bio fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about 2seventy bio are: bio, report, company, earnings, year, TSVT, late, and the most common words in the summary are: inc, bio, biotech, stock, company, news, therapeutic, . One of the sentences in the summary was: The consensus from seven analysts covering the company is for revenues of US$74.8m in 2024. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #inc #bio #biotech #stock #company #news #therapeutic.

Read more →

Youtube Subscribe

---